Get started
Author

Irina V. Sorokina

Observed names: I. Sorokina, I. V Sorokina, I. V. Sorokina, Irina Sorokina
Observed institutions: Russian Academy of Sciences, Lomonosov Moscow State University, Moscow Clinical Scientific Center, Institute of Bioorganic Chemistry, BIOCAD (India), BIOCAD (Russia)
ORCID: 0000-0002-9404-3698
Observed ORCID: 0000-0002-9404-3698
OpenAlex ID: A5073719890
Mitotic catastrophe and cancer drug resistance: A link that must to be broken
2015 · Tatiana V. Denisenko, Irina V. Sorokina, et al. · Drug Resistance Updates · 108
Involvement of autophagy in the outcome of mitotic catastrophe
2017 · Irina V. Sorokina, Tatiana V. Denisenko, et al. · Scientific Reports · 34
PDF
The Gut Microbiota Impacts Gastrointestinal Cancers through Obesity, Diabetes, and Chronic Inflammation
2024 · Konstantin A. Rumyantsev, Vera V. Polyakova, et al. · Life · 15
PDF
Prevention of febrile neutropenia in oncological patients: real-world data
2023 · Kirill V. Sapozhnikov, Irina V. Sorokina, et al. · Journal of Modern Oncology · 12
PDF
Reactive oxygen species regulate a balance between mitotic catastrophe and apoptosis
2016 · Irina V. Sorokina, Tatiana V. Denisenko, et al. · The International Journal of Biochemistry & Cell Biology · 9
Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study
2023 · Igor V. Samoylenko, Lev V. Demidov, et al. · Journal of Modern Oncology · 7
PDF
A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)
2024 · Lev Demidov, Galina Kharkevich, et al. · Frontiers in Oncology · 6
PDF
Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial
2025 · Lev Demidov, Igor Samoylenko, et al. · European Journal of Cancer · 4
Abstract 653: Proved clinical benefit of low-dose anti-CTLA4 + anti-PD-1 immunotherapy versus mono anti-PD-1 therapy in patients unresectable or metastatic melanoma: Phase III OCTAVA trial
2025 · Lev Demidov, Igor Samoylenko, et al. · Cancer Research · 4
Effectiveness and safety of empegfilgrastim (Extimia®) in patients with solid tumors receiving cytotoxic therapy: final results of the DEFENDOR study
2024 · Anton V. Snegovoy, Inessa B. Kononenko, et al. · Journal of Modern Oncology · 4
The frequency of regimens associated with high risk of febrile neutropenia and the incidence of dose-limiting neutropenia among patients receiving cytotoxic therapy for malignancies: the FLAME study results
2023 · Anton V. Snegovoy, Inessa B. Kononenko, et al. · Journal of Modern Oncology · 3
PDF
Defendor: Real-world evidence of primary prolonged G-CSF prophylaxis by empegfilgrastim for relative dose intensity compliance in patients with solid tumors—The primary analysis.
2022 · Anton Snegovoy, Alexander Dergunov, et al. · Journal of Clinical Oncology · 3
A phase I dose escalation trial of BCD-145 in patients with unresectable or metastatic melanoma.
2024 · Fedor Kryukov, Tatiana Semiglazova, et al. · Journal of Clinical Oncology · 2
Abstract P3-07-23: Defendor Special: Primary empegfilgrastim prophylaxis (prolonged G-CSF) for optimal treatment outcomes in high risk early breast cancer cohort. The interim analysis
2023 · Irina Sorokina, Inna Ganshina, et al. · Cancer Research · 2
Expression of chicken CTCF gene in COS-1 cells and partial purification of CTCF protein
2013 · E. S. Kotova, I. V. Sorokina, et al. · Biochemistry (Moscow) · 2
DEFENDOR SPECIAL: Effect of primary prophylaxis with empegfilgrastim on pCR rate after neoadjuvant TCHP in early HER2+ breast cancer patients—Matching-adjusted indirect comparison (MAIC).
2025 · Lyudmila Zhukova, Tansylu Ibragimova, et al. · Journal of Clinical Oncology · 1
PDF
INSIGHT-HER2BC: Real-world evidence of TCHP regimen to describe the best patient profile and open up questions—The interim results.
2023 · Lyudmila Zhukova, Irina Sorokina, et al. · Journal of Clinical Oncology · 1
Defendor special: Interim analysis of TCHP with primary empegfilgrastim prophylaxis (long-acting G-CSF) for treatment outcomes in early HER2+ breast cancer.
2023 · Lyudmila Zhukova, Tansylu Ibragimova, et al. · Journal of Clinical Oncology · 1
Short-term preoperative endocrine therapy allows to estimate and revert patient prognosis with further treatment plan correction in HR+ HER2- early breast cancer patients.
2022 · Lyudmila Zhukova, Inna Ganshina, et al. · Journal of Clinical Oncology · 1
Incidence of severe and febrile neutropenia in cancer patients treated with myelosuppressive chemotherapy in real clinical oncology practice: Preliminary results from the FLAME study.
2022 · Anton Snegovoy, Inessa Kononenko, et al. · Journal of Clinical Oncology · 1
Final results of the phase III OCTAVA trial: Clinical benefit of low-dose anti–CTLA-4 plus anti–PD-1 combination vs anti–PD-1 monotherapy in unresectable or metastatic melanoma.
2026 · Lev V. Demidov, Igor V. Samoylenko, et al. · Journal of Clinical Oncology
Efficacy of neoadjuvant TCHP with primary empegfilgrastim (E) prophylaxis in HER2-positive early breast cancer (HER2+ eBC): Final results of the DEFENDOR SPECIAL study.
2026 · Lyudmila Zhukova, Tansylu Ibragimova, et al. · Journal of Clinical Oncology
Efficacy and safety of the pertuzumab biosimilar BCD-178 versus the originator pertuzumab in patients with HER2-positive locally advanced breast cancer: Results from the international, double-blind, randomized, phase III PREFER trial.
2026 · Lyudmila Zhukova, Elena Artamonova, et al. · Journal of Clinical Oncology
Efficacy of neoadjuvant TCHP regimen with empegfilgrastim in early HER2-positive breast cancer: Final analysis of the DEFENDOR SPECIAL study, HER2+ BC cohort
2026 · Liudmila G. Zhukova, Tansylu M. Ibragimova, et al. · Journal of Modern Oncology
PDF
33P The impact of primary prophylaxis with empegfilgrastim (long-acting G-CSF) on pathological complete response (pCR) during TCHP in early HER2+ breast cancer patients
2025 · L. Zhukova, T. Ibragimova, et al. · Annals of Oncology
Works count: 32
Citation count: 220
H-index: 6
I10-index: 4
Year
Topic
Type